PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

August 16, 2022 updated by: Lunxiu Qin, Fudan University

Efficacy and Safety of PD-1 Antibody and Lenvatinib Plus TACE on Downstaging Hepatocellular Carcinoma With BCLC B/C

The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shanghai
      • Shanghai, Shanghai, China, 200040

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age ≥18 years old and ≤75 years old;
  2. Clinically diagnosed as hepatocellular carcinoma, stage B/C of BCLC;
  3. No history of severe arrhythmia or heart failure;
  4. No history of severe ventilation dysfunction or severe pulmonary infection;
  5. No acute or chronic renal failure, the creatinine clearance rate was >40 mL/min;
  6. Liver function Child A;
  7. Blood routine: absolute neutrophils count ≥1.5×10^9/L, Hb≥8.5g/L, PLT≥75×10^9/L;
  8. Coagulation function: INR≤2.3;
  9. ECOG score <2;
  10. No local or systemic treatment, such as TACE, RFA, targeted drugs, traditional Chinese medicine, etc., before enrollment;
  11. Expected survival ≥12 weeks;
  12. At least one lesion can be measured and evaluated by CT/MRI according to RECIST 1.1 criteria;
  13. Understand and sign the informed consent.

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Patients with other malignant tumors;
  3. patients with complicated mental illness;
  4. patients who have participated in other clinical trials in the last three months;
  5. known or suspected allergy to any drug related to the study;
  6. Patients with positive immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
  7. Patients treated with other targeted drugs, PD-L1 antibody and other immunotherapy or FOLFOX systemic chemotherapy after inclusion;
  8. Patients with ≥1 + proteinuria indicated by urine routine will receive 24-hour urine protein detection, and patients with ≥1g 24-hour urine protein will not be included in the group.
  9. Active autoimmune diseases that require systemic treatment (use of disease-alleviating agents, such as corticosteroids or immunosuppressants)
  10. Patients with uncontrolled hepatitis B/C infection
  11. Other conditions that the researcher considers not suitable for inclusion in this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: PD-1+TACE+Len
PD-1 Antibody and Lenvatinib Plus TACE
Combination product: PD-1 and Lenvatinib Plus TACE
PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resection rate
Time Frame: 6 months after downstaging treatment
Resction rate refers to the proportion of patients who can receive radical surgery after downstaging treatment.
6 months after downstaging treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse events (safety)
Time Frame: 6 months
Postoperative adverse events (safety ) will be evaluated according to the NCI CTCAE Version 4.03.The number and severity of treatment-related side effects, including AE and SAE, will be recorded during treatment.
6 months
Overall survival (OS)
Time Frame: 2 years
The duration from the date of recruitment to the date of death from any cause.
2 years
Objective response rate (ORR)
Time Frame: 6 months
ORR is defined as the percentage of participants who have a confirmed complete response or partial response according to RECIST 1.1 or mRECIST.
6 months
Progression free survival (PFS)
Time Frame: 6 months
PFS is defined as the time from enrollment of the trial to the first documented disease progression or death due to any cause.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fudan University

Investigators

  • Study Director: Lunxiu Qin, M.D, Department of Surgery, Huashan Hospital, Fudan University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Anticipated)

December 31, 2022

Study Completion (Anticipated)

December 31, 2022

Study Registration Dates

First Submitted

June 20, 2021

First Submitted That Met QC Criteria

July 13, 2021

First Posted (Actual)

July 23, 2021

Study Record Updates

Last Update Posted (Actual)

August 18, 2022

Last Update Submitted That Met QC Criteria

August 16, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HUASHAN007

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Clinical Trials on PD-1 and Lenvatinib Plus TACE

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe